When prescription drugs go OTC, ads talk less of harms: study

by Jenifer Goodwin, Healthday Reporter
When prescription drugs go OTC, ads talk less of harms: study
Two different federal agencies monitor each, researcher explains.

(HealthDay)—When prescription drugs become available over-the-counter, advertisements for the medications are far less likely to tell consumers about the potential harms and side effects, new research finds.

The reason for it, experts say, likely has to do with which federal agency regulates the marketing materials for each type of . The U.S. (FDA) regulates ads for , while ads for over-the-counter drugs are regulated by the U.S. (FTC).

The FTC has much less stringent standards than the FDA for what manufacturers have to reveal about products in their marketing materials, the researchers noted.

The FDA requires prescription drug advertising to provide consumers with a "fair balance" of risks and benefits— for drug ads, that often means rattling off a lengthy list of potential .

The FTC, on the other hand, holds drug advertisements to the same standards as other consumer products, requiring a "reasonable" standard of truthfulness.

The looser requirements mean that information about potential side effects and harm aren't included in most over-the-counter drug ads, said study author Dr. Jeremy Greene, an associate professor in the history of medicine department and the department of medicine at Johns Hopkins University.

"One of the FDA's guiding principles for regulating direct-to-consumer ads for prescription drugs is there needs to be a fair presentation of the risks and benefits," Greene explained. "The FTC has fewer requirements or specific regulations for how risks and benefits should be presented. The FTC is interested in making sure there are no fraudulent statements being made, and there is no active deception."

The findings are published in the Sept. 12 issue of the .

Greene and his colleagues analyzed print and broadcast advertisements for four commonly used drugs that were heavily marketed to consumers as prescription drugs and then approved for sale over-the-counter.

The drugs included loratadine (brand name: Claritin, sold over-the-counter since 2002), omeprazole (brand name: Prilosec, went over-the-counter in 2004), orlistat (brand name: Alli, Xenical, sold over-the-counter since 2007), and cetirizine (brand name: Zyrtec, sold over-the-counter since 2008).

When the drugs were available only by prescription, 70 percent of the ads mentioned potential harms. After the drugs were available over-the-counter, only 11 percent did, the investigators found.

After drugs became available over-the-counter, only about half of print and broadcast advertisements mentioned a drug's generic name, compared to 94 percent of when drugs were prescription-only. Knowing a drug's generic name can help consumers make sure they're not taking more than one medication that has it as a component, risking overdose, Greene explained.

To give consumers the information they need to better understand risk, the FDA should be given authority to regulate marketing of over-the-counter drugs, or perhaps the FTC should adopt guidelines similar to what the FDA requires, according to Greene.

That said, few think even the FDA's "fair balance" guidelines are sufficient enough to really inform, he added.

Drug company advertising often includes a laundry list of potential side effects. That offers consumers little way to determine which risks they should pay the most attention to, or which risks should impact their decision-making about taking the drug, said Diane Pinakiewicz, president of the National Patient Safety Foundation.

"That is fulfilling the fair balance requirements, but the real purpose should be education of the consumer on the benefits and the risks of a drug in language people can understand, and fair balance doesn't do that effectively at all," Pinakiewicz said.

With consumers getting even less information about the risks of over-the-counter drugs, she suggests people consult with their physicians or their pharmacist about any medications they're taking.

Overdoses on acetaminophen (Tylenol) or ibuprofen (Advil) have become all too common, Greene added, highlighting that even the most commonplace drugs can have a downside.

"Once a drug becomes over-the-counter, it can still be quite dangerous and possibly fatal," Greene said.

More information: The Consumer Healthcare Products Association has more on over-the-counter drug safety.

Related Stories

Despite some benefit, drug ads can be harmful to your health

Nov 12, 2009

While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize ...

FDA cracks down on untested cold medicines

Mar 02, 2011

(AP) -- The Food and Drug Administration says it will remove roughly 500 unapproved cold and allergy medications from the market as part of an ongoing campaign cracking down on ineffective prescription medications.

Recommended for you

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Drug-coated balloon catheter approved

Oct 13, 2014

(HealthDay)—The first drug-coated balloon catheter designed to clear narrowed or blocked arteries in the thigh and knee has been approved by the U.S. Food and Drug Administration.

User comments